Friday, July 10, 2026

Drug profile · INN

patiromer

patiromer (VELTASSA) is a potassium chelating agent. Associated with Seqirus (Australia) Pty Ltd.

EMA: approved TGA: approved Various (V03) V03AE09
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — patiromer

Quick answer

patiromer (VELTASSA) is a potassium chelating agent. Associated with Seqirus (Australia) Pty Ltd.

Key facts

INN patiromer
Brand VELTASSA
Mechanism Potassium chelating agent
Target Potassium
Therapeutic class Various (V03)
ATC code V03AE09

Mechanism of action

Potassium chelating agent

Primary target: Potassium

Approval history

Authority Status Date
EMA approved
TGA approved

Pipeline programs

  1. PRINCE Phase 3 · Istituto Gentili Italia · End Stage Kidney Disease on chronic dialysis therapy

Related & competitor drugs

  1. amifampridine phosphate Voltage-gated potassium channel blocker
  2. amiodarone hydrochloride HERG blocker
  3. besilesomab Various (V09)
  4. chlorzoxazone Intermediate conductance calcium-activated potassium channel protein 4 opener
  5. dalfampridine Voltage-gated potassium channel blocker
  6. deferasirox Various (V03)

Frequently asked questions

What is patiromer?

patiromer (VELTASSA) is a potassium chelating agent. Associated with Seqirus (Australia) Pty Ltd.

What is the brand name for patiromer?

VELTASSA is a marketed brand name for patiromer. Check FDA Drugs@FDA for the current US label holder and prescribing information.